The novel local-acting ileal bile acid transporter inhibitor elobixibat helps relieve chronic constipation in the short term, with well tolerated safety profile in the long term — supporting the novel approach of increasing intracolonic bile acid concentration for treating chronic constipation, two phase III studies show.
Canakinumab provides effective flare control and prevention in patients with monogenic autoinflammatory diseases, namely colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency and tumour necrosis factor receptor–associated periodic syndrome, according to the results of a phase III CLUSTER trial.
Use of zoledronic acid for 2 years appears to be effective against cancer treatment-induced bone loss in premenopausal women with breast cancer, with bone mass density values maintained for up to 3 years after cessation of treatment, according to the results of the placebo-controlled ProBone II trial.
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Lofexidine appears as good as diazepam in combating symptoms of opioid withdrawal and has better treatment retention rate than diazepam, suggesting lofexidine as a viable alternative when standard opioid-assisted therapies are unavailable, a recent study shows.
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.